Long-term Efficacy of Pramipexole in Anhedonic Depression

Summary

The purpose of the study is to assess the long-term efficacy and safety of add-on pramipexole for treatment of patients with anhedonic depression.

Timeline

Start

2023-04-21

Primary completion

2025-12-05

Completion

2025-12-05

Publications

• Ventorp F, Asp M, Olsson S, Lindahl J, Moller S, Svensson M, Angeby F, Pravdinske A, Tjernberg J, Schrey S, Stahl D, Magnusson V, Eliasson E, Agelii-Weber A, Stalhammar E, van Westen D, Deierborg T, Mansson KNT, Pizzagalli DA, Hammar A, Tornberg AB, Bjorkstrand J, Lindqvist D. Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial. Nat Med. 2026 Jun 12. doi: 10.1038/s41591-026-04465-9. Online ahead of print.
• Lindahl J, Asp M, Stahl D, Tjernberg J, Eklund M, Bjorkstrand J, van Westen D, Jensen J, Mansson K, Tornberg A, Svensson M, Deierborg T, Ventorp F, Lindqvist D. Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden. BMJ Open. 2023 Nov 30;13(11):e076900. doi: 10.1136/bmjopen-2023-076900.

Drugs

Indications